Loading
A phase 1/2 trial of PM8002 in triple-negative breast cancer, run by Biotheus Inc., active and no longer recruiting.
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC is a phase 1/2 interventional study registered as NCT05918133 by Biotheus Inc., with 42 participants enrolled, started 2022-07-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: PM8002 and nab-paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, BioNTech, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/